Sabat, Robert
Wolk, Kerstin
Loyal, Lucie
Döcke, Wolf-Dietrich
Ghoreschi, Kamran
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (FOR 2497/TP02 (GH133/2‐1))
Novartis Pharma
Article History
Received: 12 February 2019
Accepted: 22 March 2019
First Online: 26 April 2019
Compliance with ethical standards
:
: KG has been a consultant, lecturer, or investigator for AbbVie Deutschland GmbH & Co. KG, Almirall, Biogen IDEC GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Celgene GmbH, Eli Lilly and Company, Janssen-Cilag GmbH, MSD Sharp & Dohme, Novartis Pharmaceuticals, Pfizer Deutschland GmbH, and Roche.RS has received research grants or honoraria for participation in advisory boards, clinical trials or as speaker for one or more of the following: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG, Bayer Schering Pharma AG, Biogen IDEC GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, Celgene GmbH, Celgene International II Sàrl, Charité Research Organisation GmbH, Dr. Willmar Schwabe GmbH & Co. KG, Flexopharm GmbH & Co. KG, Generon Corporation Ltd., Janssen-Cilag GmbH, Novartis Pharma GmbH, Parexel International GmbH, Pfizer Deutschland GmbH, Sanofi–Aventis Deutschland GmbH, TFS GmbH, UCB Biopharma SPRL.KW has been a consultant, lecturer, or investigator for AbbVie Deutschland GmbH & Co. KG, Bayer Schering Pharma AG, Celgene GmbH, Celgene International II Sàrl, Generon Corporation Ltd., Janssen-Cilag GmbH, Novartis Pharma GmbH, Sanofi–Aventis Deutschland GmbH, and UCB Biopharma SPRL.